PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients
Source: SeekingAlpha
2026-05-13 10:11:47 ET
More on PDS Biotechnology
- PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
- PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
- PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment
- Seeking Alpha’s Quant Rating on PDS Biotechnology
- Historical earnings data for PDS Biotechnology
Read the full article on Seeking Alpha
For further details see:
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients
PDS Biotechnology Corporation
NASDAQ: PDSB
PDSB Trading
-3.99% G/L:
$0.73 Last:
190,966 Volume:
$0.7739 Open:
PDSB Latest News
May 13, 2026 07:00:00 am
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
May 06, 2026 08:00:00 am
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
$35,486,232
44,474,119
0.07%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
